ALAMEDA, Calif.--(BUSINESS WIRE)--LifeMap Sciences, Inc. announced today the release of LifeMap Discovery version 1.2 (discovery.lifemapsc.com). LifeMap Discovery is a state-of-the-art roadmap of embryonic development and stem cell biology. The product integrates embryonic development and stem cell biology, molecular, cellular, anatomical, and disease-related information, and provides data-mining capabilities and bioinformatics applications. As such, it is a unique and powerful tool for research and discovery in multiple disciplines, including stem cell biology, developmental biology and disease mechanisms and etiology.

LifeMap Discovery version 1.2 provides enhanced features related to stem cell therapeutic development

LifeMap Discovery is a key component in LifeMaps integrated database suite, a discovery platform for biomedical and stem cell research, which also includes GeneCards, the leading human gene database, and MalaCards, the human disease database.

LifeMap Discovery version 1.2 new features and information include the following:

LifeMap Discovery version 1.2 provides enhanced features related to stem cell therapeutic development, said Ronit Shtrichman, Ph.D., MBA, Vice President of Biology at LifeMap Sciences. This version includes substantially upgraded information about stem cells with potential therapeutic applications and stem cell differentiation protocols. It also enables researchers to identify genes specifically expressed during embryonic development and stem cells differentiation, providing the means to generate desired cell types for therapeutic applications.

The extensive coverage of the stem cell therapy pipeline and high throughput gene expression data are significant steps forward in developing our premium model, and are of significant interest to companies developing cell-based therapies. Coupled with the commercial offering of recombinant proteins and PureStem progenitors, it is an important milestone for commercialization of the LifeMap Discovery platform, stated Yaron Guan-Golan, Head of Marketing at LifeMap Sciences.

About LifeMap Sciences, Inc.

LifeMap Sciences (www.lifemapsc.com) core technology and business is based on the LifeMap Integrated Biomedical Knowledgebase, the discovery platform for biomedical and stem cell research. This web-based platform includes GeneCards, the leading human gene compendium; LifeMap Discovery, the embryonic development, stem cell research and regenerative medicine compendium; and MalaCards, the human disease compendium. According to Google Analytics, the sites have generated more than 2,000,000 unique visitors with more than 13,000,000 page views, from more than 3,000 universities, institutions and biomedical companies in the past 12 months.

Via LifeMap BioReagents, LifeMap offers leading edge reagents to researchers in academia, research hospitals, and biotech and pharma companies. LifeMap is BioTimes principal marketing subsidiary for research products, including PureStem human progenitor cells, PureStem packages, clinical and research grade human embryonic stem cell (hES) lines, culture media, and cell differentiation kits. The eCommerce portal also offers select recombinant proteins, including growth factors, signaling molecules, differentiation factors, cytokines and chemokines that complement BioTimeresearch product lines.

In therapeutic discovery collaboration with BioTime, LifeMaps scientists utilize the Integrated Biomedical Knowledgebase to aid in the development of BioTimes proprietary library of more than 200 PureStem human progenitor cell types into products for the treatment of human diseases, especially degenerative diseases that might be treatable with cell replacement therapies. A bioinformatics platform developed by LifeMap is used to select the PureStem cells that are most likely to be useful in developing cell-based regenerative medicine therapies for a wide range of diseases.

Read the original:
LifeMap Sciences Announces Release of LifeMap Discovery™ Version 1.2 With Extensive Stem Cell Therapy Data